trial failure
Acceleron terminates drug candidate following facioscapulohumeral muscular dystrophy failure
September 17, 2019Manufacturing and Production, Research and Development Acceleron, pharma, trial failure
Acceleron Pharma has seen its stock fall by almost 4% after it unveiled new Phase 2 data confirming that its …
Pfizer’s Lyrica fails at Phase 3 in treating primary generalised tonic-clonic (PGTC) seizures
May 28, 2019Manufacturing and Production, Research and Development, Sales and Marketing Lyrica, Pfizer, epilepsy, pharma, trial failure
Pfizer has unveiled new Phase 3 data on the effectiveness of Lyrica (pregabalin) in the adjunctive treatment of primary generalised …
AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit
May 20, 2019Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure
AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …
Boehringer’s Pradaxa fails to meet Phase 3 endpoint in preventing recurrent stroke
May 20, 2019Research and Development, Sales and Marketing Boehringer, Pradaxa, pharma, stroke, trial failure
Boehringer has announced that Pradaxa (dabigatran etexilate mesylate) has failed to meet its primary endpoint in its Phase 3 study, …
BMS blockbuster Opdivo falls short at Phase 3 in MGMT-unmethylated glioblastoma multiforme
May 10, 2019Medical Communications, Research and Development BMS, Bristol-Myers Squibb, glioblastoma multiforme, pharma, trial failure
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating …
Allergy Therapeutics’ adjuvanted birch allergoid drug shocks with Phase 3 failure
March 18, 2019Research and Development, Sales and Marketing allergy, allergy therapeutics, pharma, trial failure
UK-based biotech firm Allergy Therapeutics has been left disappointed after it became evident that its adjuvanted birch allergoid product failed …
Lilly’s Lartruvo/chemo combo surprises with Phase 3 failure in soft tissue carcinoma
January 21, 2019Research and Development, Sales and Marketing Cancer, Eli Lilly, carcinoma, chemotherapy, pharma, trial failure
Eli Lilly has reluctantly pulled back the curtain on new Phase 3 data for its platelet-derived growth factor receptor alpha …
Verona’s shares drop 34% on Phase 2 failure of nebulised ensifentrine in COPD
January 15, 2019Manufacturing and Production, Research and Development Boehringer, COPD, Stiolto Respimat, pharma, trial failure, verona pharma
Verona Pharma has seen its shares crater following the Phase 2 failure of its nebulised ensifentrine, known as RPL554, in …
Phase 3 failure of asthma therapy sends Vectura’s ailing shares falling
November 27, 2018Manufacturing and Production, Research and Development asthma, pharma, trial failure, vectura
Vectura has announced it is terminating development of its severe asthma therapy VR475, an inhaled formulation of the corticosteroid budesonide, …
Zynerba’s cannabis-based transdermal patch fails at Phase 1, shares slide 21%
July 6, 2018Medical Communications, Research and Development GW Pharma, Zynerba, cannabidinol, cannabinol, cannabis, pharma, trial failure
As public focus on the issue of medicinal cannabis continues to grow, Zynerba Pharmaceuticals has announced that its transdermal tetrahydrocannabinol …
Summit Pharma axes Duchenne drug after Phase 2 failures
June 28, 2018Research and Development Duchenne Muscular Dystrophy, Summit Pharmaceuticals, pharma, trial failure
Summit Therapeutics has revealed it is to terminate development of its Duchenne muscular dystrophy (DMD) drug ezutromid after it failed …
Keytruda combo fails at Phase 3 in metastatic melanoma
April 9, 2018Research and Development, Sales and Marketing Incyte, MSD, keytruda, pharma, trial failure
Shares in biopharma firm Incyte were sent reeling by as much as 20% when the company announced that the results …
Anthera pulls the plug on Sollpura after Phase 3 failure, shares plummet 84%
March 13, 2018Manufacturing and Production, Research and Development Anthera, Eli Lilly, Sollpura, pharma, trial failure
Anthera Pharmaceuticals has announced that it is to terminate development of its investigational pancreatic enzyme replacement therapy (PERT) Sollpura after …
VBL Therapeutics’ shares plummet on Phase 3 glioblastoma failure
March 9, 2018Medical Communications, Research and Development VBL, VBL Therapeutics, glioblastoma, pharma, trial failure
Israeli drug development firm VBL Therapeutics has been left reeling after it announced that its lead oncology product ofranergene obadenovec, …
Dermira terminates acne drug after Phase 3 failure, wiping $667m from market value
March 5, 2018Manufacturing and Production, Research and Development Dermira, acne, pharma, trial failure
Skin specialist biopharma firm Dermira has seen its stock crash and burn following the announcement that it plans to terminate …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
